Access Program Information
Gastroparesis is a digestive disorder in which motility of the stomach is either slowed or
absent. The gastroparesis prevents normal digestion from occurring. The purpose of this
study is to provide oral Domperidone offered under the U.S. Food and Drug Administration
(FDA) expanded access program, to patients that, based on the treating doctor’s assessment,
could benefit from , a prokinetic effect for the relief of refractory gastroesophageal
reflux disease with upper gastrointestinal (GI) symptoms, gastroparesis, and chronic
constipation.